Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080209 | 1.00 | TLR9 (0.65) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL906154 | 0.96 | TLR9 (0.69) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL23726903 | 0.93 | ACHE (0.67) | ACHEBACE1ENPP1AURKAPDGFRB | |
| SCHEMBL29055014 | 0.87 | ACHE (0.64) | ACHEBACE1ENPP1AURKAPDGFRB | |
| SCHEMBL30080204 | 0.85 | ENPP1 (0.66) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL23726390 | 0.85 | ENPP1 (0.66) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL21415489 | 0.85 | ACHE (0.61) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL25656100 | 0.85 | KIT (0.53) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL23726611 | 0.84 | TLR9 (0.71) | TLR9ACHEBACE1ENPP1AURKA | |
| SCHEMBL30080195 | 0.84 | TLR9 (0.71) | TLR9ACHEBACE1ENPP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4100394-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115362145-A | Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20210253556-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. | 2021-08-19 | — | — | US | disclosed |
| WO-2021158829-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | TLR9 2494/4885ACHE 939/4885BACE1 1502/4885 |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | TLR9 2494/4885ACHE 939/4885BACE1 1502/4885 |
| US-20210253556-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | TLR9 2494/4885ACHE 939/4885BACE1 1502/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | TLR9 2047/4885ACHE 721/4885BACE1 896/4885 |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | TLR9 2494/4885ACHE 939/4885BACE1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.